(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 17.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.62%.
Anaptysbio's revenue in 2025 is $57,172,000.On average, 6 Wall Street analysts forecast ANAB's revenue for 2025 to be $1,750,805,505, with the lowest ANAB revenue forecast at $365,144,184, and the highest ANAB revenue forecast at $3,653,571,848. On average, 5 Wall Street analysts forecast ANAB's revenue for 2026 to be $1,986,932,077, with the lowest ANAB revenue forecast at $365,144,184, and the highest ANAB revenue forecast at $3,653,571,848.
In 2027, ANAB is forecast to generate $3,066,785,144 in revenue, with the lowest revenue forecast at $2,096,536,190 and the highest revenue forecast at $3,665,439,034.